Cyclacel Pharmaceuticals ROCE 2024

Cyclacel Pharmaceuticals Aktienanalyse

What does Cyclacel Pharmaceuticals do?

Cyclacel Pharmaceuticals Inc was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. The company was established by Dr. David Glover, an experienced biotechnology expert, and Dr. Paul Andrews, an oncology pioneer. Cyclacel Pharmaceuticals is a company specializing in the research and development of cancer drugs. It has two main divisions: clinical drug development and drug discovery. The company's business model is to develop innovative cancer drugs to meet the needs of patients with various types of cancer. The company utilizes an innovative approach by researching and developing cyclin-dependent kinase inhibitors (CDKIs) that aim to exploit the specific vulnerabilities of cancer cells. Cyclacel Pharmaceuticals currently offers four products: Seliciclib, Sapacitabin, CYC065, and CYC140. Seliciclib is a CDKI inhibitor that is currently in clinical development and being studied in a phase 2 trial for advanced cancer patients. Sapacitabin is a CDKI stabilizer that is currently being studied in a phase 3 trial for patients with acute myeloid leukemia (AML). CYC065 is a CDKI inhibitor that is still in preclinical development and currently being tested in drug discovery. CYC140 is another CDKI target that is in preclinical development and aims to eliminate cancer cells. Cyclacel Pharmaceuticals has achieved many significant milestones in its history, including the FDA approval of Seliciclib and Sapacitabin as orphan drugs for the treatment of AML. The company has also formed important partnerships with other pharmaceutical companies to further develop and distribute its drug class. Overall, Cyclacel Pharmaceuticals pursues a promising strategy in the fight against cancer through the research and development of CDKI regulators. Although the company has only a few products on the market, it is well positioned to continue growing and developing innovative drugs that can improve patients' lives. Cyclacel Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Cyclacel Pharmaceuticals's Return on Capital Employed (ROCE)

Cyclacel Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Cyclacel Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Cyclacel Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Cyclacel Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Cyclacel Pharmaceuticals Stock

What is the ROCE (Return on Capital Employed) of Cyclacel Pharmaceuticals this year?

The ROCE of Cyclacel Pharmaceuticals is -41.93 undefined this year.

How has the ROCE (Return on Capital Employed) of Cyclacel Pharmaceuticals developed compared to the previous year?

The ROCE of Cyclacel Pharmaceuticals has increased by 2,931.99% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Cyclacel Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that Cyclacel Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Cyclacel Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that Cyclacel Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Cyclacel Pharmaceuticals impact the company?

An increase in the ROCE of Cyclacel Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Cyclacel Pharmaceuticals affect the company?

A decrease in ROCE of Cyclacel Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Cyclacel Pharmaceuticals?

Some factors that can affect Cyclacel Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Cyclacel Pharmaceuticals so important for investors?

The ROCE of Cyclacel Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Cyclacel Pharmaceuticals take to improve the ROCE?

To improve the ROCE, Cyclacel Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Cyclacel Pharmaceuticals pay?

Over the past 12 months, Cyclacel Pharmaceuticals paid a dividend of 0.15 USD . This corresponds to a dividend yield of about 9.26 %. For the coming 12 months, Cyclacel Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Cyclacel Pharmaceuticals?

The current dividend yield of Cyclacel Pharmaceuticals is 9.26 %.

When does Cyclacel Pharmaceuticals pay dividends?

Cyclacel Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Cyclacel Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cyclacel Pharmaceuticals located?

Cyclacel Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cyclacel Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cyclacel Pharmaceuticals from 8/1/2016 amounting to 0.15 USD, you needed to have the stock in your portfolio before the ex-date on 7/13/2016.

When did Cyclacel Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/1/2016.

What was the dividend of Cyclacel Pharmaceuticals in the year 2023?

In the year 2023, Cyclacel Pharmaceuticals distributed 0 USD as dividends.

In which currency does Cyclacel Pharmaceuticals pay out the dividend?

The dividends of Cyclacel Pharmaceuticals are distributed in USD.